Related Experiment Videos
Non-invasive MRS in new anticancer drug development.
P Workman1, R J Maxwell, J R Griffiths
1CRC Department of Medical Oncology, University of Glasgow, UK.
NMR in Biomedicine
|September 1, 1992
Summary
Magnetic Resonance Spectroscopy (MRS) offers non-invasive insights into anticancer drug pharmacokinetics and pharmacodynamics. While sensitive to drug-target interactions, its application requires careful consideration of limitations like signal quenching.
Area of Science:
- Pharmacology and Drug Development
- Medical Imaging and Spectroscopy
Background:
- Rational anticancer drug development necessitates comprehensive pharmacological data.
- Early clinical trials are crucial for hypothesis testing in drug efficacy.
- Non-invasive techniques are valuable for assessing drug behavior in vivo.
Purpose of the Study:
- To illustrate the advantages and limitations of Magnetic Resonance Spectroscopy (MRS) in evaluating anticancer drugs.
- To assess the utility of MRS for pharmacokinetic and pharmacodynamic studies of novel fluorinated anticancer agents.
Main Methods:
- Utilized 19F MRS to study two fluorine-containing anticancer drugs: a difluoro analogue of chlorambucil and fluoromisonidazole (Ro 07-0741).
- Investigated drug accumulation in tumors and potential for detecting tumor hypoxia.
Main Results:
- Identified limitations of MRS, including signal quenching due to protein binding and insufficient sensitivity for highly potent drugs like difluorochlorambucil.
- Demonstrated that fluoromisonidazole accumulates in tumors.
- Fluoromisonidazole shows potential as a chemical probe for detecting tumor hypoxia via 19F MRS.
Conclusions:
- 19F MRS is a valuable tool for non-invasive pharmacokinetic and pharmacodynamic assessment of anticancer drugs.
- Challenges such as signal quenching and sensitivity must be addressed for broader MRS application.
- Fluoromisonidazole shows promise for in vivo tumor hypoxia detection using 19F MRS.